Abstract: Provided is a solid preparation having an excellent stability and being useful for treating or improving (or alleviating) a urination disorder regardless of the degree or presence of prostatomegaly. The solid preparation contains a 2-oxapregnane compound represented by the following formula (1) as an active ingredient, and a carrier. In the formula, R1 to R3 each represent an alkyl group such as a methyl group, R4 represents an alkylcarbonyl group such as an acetyl group, X represents a halogen atom such as a chlorine atom, and Y represents a hydroxyl group or oxo group bonded to the 11-position, 15-position, or 16-position of the steroid skeleton. The carrier contains a first carrier and/or a second carrier; the first carrier is not a metal salt-form, and the second carrier is a polyvalent metal salt-form of an inorganic acid.

Abstract: A joining structure of a packaging container is divided into at least two packaging members, and the joining structure includes: first slits formed in a dividing direction and located on both side of at least one corner of a joining-side end of a first packaging member, the first packaging member and a second packaging member being joined to each other; an engaging corner formed at a joining-side end of the second packaging member, the engaging corner being engaged with each of the first slits and being located on an inner side of a corner of the first packaging member, the engaging corner being formed at a corner corresponding to the corner of the first packaging member; and a cover that continues to the engaging corner and is located to cover an outer side of a joining end of the first packaging member on an outer side of the first slits.